A	B	C
1	Main
2		Brand Name	Kevzara
3		Generic Name	REGN88
4		Mechanism	fully human monoclonal antibody against IL-R6
5		Indication	RA, ankylosing spondylitis
6		Competition	Actemra (IL-6R antibody tocilizumab fr DNA), TNFs, etc
7		Economics	Sanofi
8		Administration
9		Clinical Trials
10			Phase 2/3 in RA -- initial results expected mid-2011
11
12
13			Phase 2 in ankylosing spondylitis -- initial results expected mid-2011
14
15
16			Phase 1 data from EULAR 2010 and ACR 2010
17			dose-related reductions in biomarkers of inflammation